Liver disease

More physiologically and pathologically relevant preclinical human liver models are needed for drug liver liability assessment and liver disease modeling. While Drug-Induced Liver Injury (DILI) remains a major safety concern, several recent high-profile NAFLD/NASH clinical trial failures further highlight this critically unmet need. With the advances in 3D culture, we and others have demonstrated the […]

More physiologically and pathologically relevant preclinical human liver models are needed for drug liver liability assessment and liver disease modeling. This app note offers insight and media for drug discovery.  While Drug-Induced Liver Injury (DILI) remains a major safety concern, several recent high-profile NAFLD/NASH clinical trial failures further highlight this critically unmet need. With the advances […]

Calliditas Therapeutics has been granted Fast Track designation by the US Food and Drug Administration (FDA) for its NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis (PBC). Setanaxib has previously been granted orphan drug designation for PBC in the US and Europe. “We are delighted […]